☆ 4.6 Article

Clinical Characteristics, Response to Platinum-Based Chemotherapy and Poly (Adenosine Phosphate-Ribose) Polymerase Inhibitors in Advanced Lung Cancer Patients Harboring BRCA Mutations

CANCERS (2023)

Related references

Note: Only part of the references are listed.

Article Multidisciplinary Sciences

Identification of BRCA1/2 mutation female carriers using circulating microRNA profiles

Kevin Elias et al.

Summary: In this study, we found 19 miRNAs associated with BRCA1/2 mutations, and 10 of them were used for diagnostic classification. The logistic regression model achieved high sensitivity and specificity in an independent validation cohort, offering a potential cost-effective method to identify BRCA1/2 mutations in high-risk cancer patients.

NATURE COMMUNICATIONS (2023)

Add to Collection

Article Oncology

BRCA mutations detected by tumour next-generation sequencing in non-small cell lung cancer: impact on response to therapy and disease course

Roi Tschernichovsky et al.

Summary: The prevalence of BRCA mutations in non-small cell lung cancer (NSCLC) is low, but it has significant impact on disease course and treatment response. NSCLC patients with pBRCA mutations have a lower smoking history and show prolonged progression-free survival with first-line chemo-immunotherapy.

TRANSLATIONAL LUNG CANCER RESEARCH (2023)

Add to Collection

Article Oncology

Biallelic BRCA Loss and Homologous Recombination Deficiency in Nonbreast/Ovarian Tumors in Germline BRCA1/2 Carriers

Dylane Wineland et al.

JCO Precision Oncology (2023)

Add to Collection

Article Oncology

BRCA mutations detected by tumour next-generation sequencing in non-small cell lung cancer: impact on response to therapy and disease course

Roi Tschernichovsky et al.

Summary: The prevalence and clinical relevance of BRCA mutations in NSCLC were evaluated. It was found that 24.5% of NSCLC patients had BRCA variants, and these patients had a less significant smoking history and prolonged progression-free survival with first-line chemo-immunotherapy.

TRANSLATIONAL LUNG CANCER RESEARCH (2023)

Add to Collection

Article Oncology

Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants

Shuai Li et al.

Summary: This study aims to provide precise age-specific risk estimates of cancers other than female breast and ovarian cancers associated with pathogenic variants (PVs) in BRCA1 and BRCA2 for effective cancer risk management.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies

Yonina R. Murciano-Goroff et al.

Summary: The loss of BRCA1/2 is associated with a homologous recombination deficiency phenotype, which is lineage dependent. In BRCA-associated cancers, this phenotype makes the tumors sensitive to PARP inhibitors and platinum-therapies. In this study, the researchers analyzed sequencing data from 31,927 patients and identified 846 patients with germline BRCA1/2 variants across 43 different cancer types, including 11 with somatic reversion mutations. They found two reversion mutations in non-BRCA-associated lung and esophagogastric adenocarcinomas, which were detected following platinum therapy. Whole exome sequencing confirmed the homologous recombination deficiency phenotype of these tumors. The study suggests that reversion mutations in BRCA1/2 can indicate prior BRCA-mediated tumorigenesis in non-canonical histologies.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Medicine, General & Internal

Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial

Dean A. Fennell et al.

Summary: This study investigates the relationship between HRD modification and the sensitivity to PARP inhibitor olaparib in patients with metastatic non-small cell lung cancer who exhibited partial responses to platinum doublet-based chemotherapy.

ECLINICALMEDICINE (2022)

Add to Collection

Article Oncology

JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer

Suresh S. Ramalingam et al.

Summary: The combination of niraparib and pembrolizumab showed promising clinical activity in patients with advanced and/or metastatic NSCLC, with significant objective response rates observed in patients with high levels of PD-L1 expression. This combination therapy also demonstrated manageable safety profiles consistent with the known side effects of each drug individually, supporting further investigation into its potential as a treatment option.

CANCER (2022)

Add to Collection

Article Oncology

Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G

Taofeek K. Owonikoko et al.

Summary: The study found that single agent talazoparib did not show sufficient efficacy in a biomarker defined subset of squamous lung cancer with homologous recombination repair deficiency.

CLINICAL LUNG CANCER (2021)

Add to Collection

Article Oncology

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Luis Paz-Ares et al.

Summary: The combination of first-line nivolumab plus ipilimumab with a limited course of chemotherapy showed a significant improvement in overall survival for patients with advanced non-small-cell lung cancer, supporting it as a new treatment option for this patient population.

LANCET ONCOLOGY (2021)

Add to Collection

Meeting Abstract Oncology

A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A).

Jonathan W. Riess et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Olaparib for Metastatic Castration-Resistant Prostate Cancer

J. de Bono et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity

Ethan S. Sokol et al.

JCO PRECISION ONCOLOGY (2020)

Add to Collection

Article Genetics & Heredity

Detecting the mutational signature of homologous recombination deficiency in clinical samples

Doga C. Gulhan et al.

NATURE GENETICS (2019)

Add to Collection

Article Multidisciplinary Sciences

Tumour lineage shapes BRCA-mediated phenotypes

Philip Jonsson et al.

NATURE (2019)

Add to Collection

Article Medicine, General & Internal

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Talia Golan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Oncology

Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization

Luna Kadouri et al.

LUNG CANCER (2019)

Add to Collection

Review Oncology

Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy

Ferdinandos Skoulidis et al.

NATURE REVIEWS CANCER (2019)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer

L. Gandhi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Review Oncology

Role of BRCA Mutations in the Modulation of Response to Platinum Therapy

Sanghamitra Mylavarapu et al.

FRONTIERS IN ONCOLOGY (2018)

Add to Collection

Article Oncology

Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer

Suresh S. Ramalingam et al.

CLINICAL CANCER RESEARCH (2017)

Add to Collection

Article Oncology

Germline Mutations in DNA Repair Genes in Lung Adenocarcinoma

Erin M. Parry et al.

JOURNAL OF THORACIC ONCOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

Mark Robson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Oncology

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

Emmet J. Jordan et al.

CANCER DISCOVERY (2017)

Add to Collection

Article Oncology

Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers

Haley Streff et al.

ONCOLOGIST (2016)

Add to Collection

Article Oncology

Germline BRCA1 mutations increase prostate cancer risk

D. Leongamornlert et al.

BRITISH JOURNAL OF CANCER (2012)

Add to Collection

Article Multidisciplinary Sciences

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

H Farmer et al.

NATURE (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.